# Rigel Pharmaceuticals, Inc. (RIGL)

- Sector: Healthcare · Industry: Biotechnology
- SEC CIK: 0001034842 ([filings on EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001034842))
- Full page: https://inspectstocks.com/stocks/rigl
- Data as of: price 2026-09-25; newest filing used 2026-08-04; latest fiscal period ended 2026-06-30

## Grade

**B+** on the balance-sheet rubric used for lenders, 3 of 4 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | passed | $321.9M |  |
| Earnings growing overall | passed | $321.9M | -$37.8M |
| Earnings growing recently | failed | $321.9M | $367M |
| Earns well on its assets | passed | 61.8% |  |
| Book value per share growing | not answerable | $20.78 | -$0.80 |

Business quality (the + / − mark): 5 of 6 checks passed.

| Check | Result | Now | Before |
| --- | --- | --- | --- |
| Profitable | passed | 116.3% |  |
| Healthy profit margin | passed | 116.3% |  |
| Strong operating margin | passed | 31.5% |  |
| Good return on equity | passed | 82.2% |  |
| Debt under control | passed | 0.14 |  |
| Turns sales into cash | failed | -26.8% |  |

How the grade works: the letter counts failed checks (none → A, one → B, two → C, three → D, four or more → F). It is built from SEC filings only — the share price never enters it — and describes the business, not whether the stock is worth buying.

## Key figures

In US dollars, as filed.

| Measure | Value |
| --- | --- |
| Revenue, trailing twelve months | $276.8M |
| Net income, trailing twelve months | $321.9M |
| Net margin | 116.3% |
| Operating margin | 31.5% |
| Return on equity | 82.2% |
| Debt to equity | 0.14 |
| Diluted EPS, trailing twelve months | $16.88 |
| Share price | $48.18 |
| Market value | $900M |
| Price / earnings | 2.9x |
| Price / sales | 3.3x |

## More on this company

- [Overview](https://inspectstocks.com/stocks/rigl)
- [Financial statements](https://inspectstocks.com/stocks/rigl/financials)
- [Competitors](https://inspectstocks.com/stocks/rigl/peers)
- [Earnings](https://inspectstocks.com/stocks/rigl/earnings)

---

Source: InspectStocks, built from the company’s own SEC filings. This describes a business — it is not investment advice and not a recommendation to buy or sell anything.